(Q39501948)

12 September 2017

1 reference

title

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure (English)

1 reference

12 September 2017

arterial hypertension

0 references

heart failure

0 references

congestive heart failure

1 reference

1 reference

P A Todd

1

1 reference

12 September 2017

R C Heel

series ordinal

2

1 reference

12 September 2017

language of work or name

1 reference

1 March 1986

1 reference

12 September 2017

1 reference

12 September 2017

31

1 reference

12 September 2017

198-248

1 reference

12 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198631030-00002

12 September 2017

0 references

cites work

Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans

1 reference

12 December 2020

Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade

1 reference

12 December 2020

Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat

1 reference

12 December 2020

Cardiac and hormonal effects of enalapril in hypertension

1 reference

12 December 2020

Enalapril and autonomic reflexes and exercise performance

1 reference

12 December 2020

Safety and efficacy of enalapril. Summing up the evidence

1 reference

12 December 2020

Peripheral large arteries and the response to antihypertensive treatment

1 reference

12 December 2020

The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects

1 reference

12 December 2020

The angiotensin converting enzyme inhibitor enalapril and its effects on renal function

1 reference

12 December 2020

Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure

1 reference

12 December 2020

Central Effects of Converting Enzyme Inhibitors

1 reference

12 December 2020

Comparative Studies: Enalapril Versus Hydrochlorothiazide as First-Step Therapy for the Treatment of Primary Hypertension

1 reference

12 December 2020

Time Course and Effect of Sodium Intake on Vascular and Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1 reference

12 December 2020

Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421)

1 reference

12 December 2020

Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide.

1 reference

12 December 2020

A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421

1 reference

12 December 2020

Renal Kallikrein-Kinin System and the Depressor Effect of Angiotensin Converting Enzyme Inhibitors MK 421, SA 446, And Captopril In Rats

1 reference

12 December 2020

The efficacy and safety of enalapril in moderate to severe essential hypertension

1 reference

12 December 2020

Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats

1 reference

12 December 2020

Enalapril for severe congestive heart failure. A double-blind study

1 reference

12 December 2020

The renin-angiotensin system in the control of systemic arterial pressure

1 reference

12 December 2020

Perspectives on systolic hypertension. The Framingham study.

1 reference

12 December 2020

Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria

1 reference

12 December 2020

Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat

1 reference

12 December 2020

Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Evaluation by two methods of blood pressure measurement

1 reference

12 December 2020

Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid

1 reference

12 December 2020

Captopril and Enalapril

1 reference

12 December 2020

Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors: past, present, and bright future

1 reference

12 December 2020

Resolution of captopril-induced rash after substitution of enalapril

1 reference

12 December 2020

Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activity

1 reference

12 December 2020

Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril)

1 reference

12 December 2020

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

1 reference

12 December 2020

Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats

1 reference

12 December 2020

Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension

1 reference

12 December 2020

Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure

1 reference

12 December 2020

The physiological disposition and metabolism of enalapril maleate in laboratory animals

1 reference

12 December 2020

Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety

1 reference

12 December 2020

Self poisoning with enalapril

1 reference

12 December 2020

Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition

1 reference

12 December 2020

The Therapeutic use of a new Potassium-Sparing Diuretic, Amiloride, and a Converting Enzyme Inhibitor, Mk-421, in Preventing Hypokalemia Associated with Primary and Secondary Hyperaldosteronism

1 reference

12 December 2020

Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension.

1 reference

12 December 2020

Acute and long-term response to enalapril in congestive failure

1 reference

12 December 2020

Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension

1 reference

12 December 2020

Enalapril in essential hypertension

1 reference

12 December 2020

Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension

1 reference

12 December 2020

Sustained haemodynamic effects of enalapril in left ventricular failure

1 reference

12 December 2020

Angiotensin II-Mediated Vasoconstriction in Chronic Congestive Heart Failure, and Response to Converting Enzyme Inhibition

1 reference

12 December 2020

Enalapril (MK421) activation in man: importance of liver status

1 reference

12 December 2020

Effect of vasodilators on survival in chronic congestive heart failure

1 reference

12 December 2020

A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats

1 reference

12 December 2020

Successful management of severe congestive cardiac failure with enalapril

1 reference

12 December 2020

New potent inhibitors of angiotensin converting enzyme

1 reference

12 December 2020

Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure

1 reference

12 December 2020

A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Absence of cross-reactivity between captopril and enalapril

1 reference

12 December 2020

Kinetic and metabolic aspects of enalapril action

1 reference

12 December 2020

Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension

1 reference

12 December 2020

Psychotropic effects of enalapril maleate in normal volunteers.

1 reference

12 December 2020

Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats

1 reference

12 December 2020

Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension

1 reference

12 December 2020

Physiological effects of short-term treatment with enalapril in hypertensive patients

1 reference

12 December 2020

Plasma renin substrate concentration during chronic propranolol therapy

1 reference

12 December 2020

Acute and subacute haemodynamic effects of enalapril. Non-invasive studies of a new converting enzyme inhibitor for antihypertensive treatment

1 reference

12 December 2020

Reversible acute renal failure during enalapril treatment in patient with chronic glomerulonephritis without renal artery stenosis

1 reference

12 December 2020

Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril

1 reference

12 December 2020

Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension

1 reference

12 December 2020

Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen

1 reference

12 December 2020

Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model

1 reference

12 December 2020

Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): A new angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Clinical and hemodynamic experience with enalapril in congestive heart failure.

1 reference

12 December 2020

Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats

1 reference

12 December 2020

Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics.

1 reference

12 December 2020

Enalapril maleate and a lysine analogue (MK-521): disposition in man

1 reference

12 December 2020

Acute effects of MK421, a new angiotensin coverting enzyme inhibitor, in man

1 reference

12 December 2020

Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart

1 reference

12 December 2020

The effect of enalapril on serum prolactin

1 reference

12 December 2020

Long-term antihypertensive, metabolic and cellular effects of enalapril

1 reference

12 December 2020

The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension

1 reference

12 December 2020

Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril

1 reference

12 December 2020

Increased renal plasma flow in long-term enalapril treatment of hypertension

1 reference

12 December 2020

Antihypertensive effect of MK-421 in rats. Role of the renal kallikrein-kinin system

1 reference

12 December 2020

Effect of antihypertensive therapy on left ventricular function and myocardial perfusion at rest and during exercise

1 reference

12 December 2020

Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat

1 reference

12 December 2020

Enalapril, a rash, and captopril

1 reference

12 December 2020

Parallel adrenal and renal abnormalities in young patients with essential hypertension

1 reference

12 December 2020

Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.

1 reference

12 December 2020

Enalapril in the treatment of hypertension associated with impaired renal function

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension

1 reference

12 December 2020

Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy

1 reference

12 December 2020

Overall tolerance and safety of enalapril

1 reference

12 December 2020

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study

1 reference

12 December 2020

Converting-enzyme inhibitor administration lowers urinary free 19-nor-deoxycorticosterone levels

1 reference

12 December 2020

A comparative study of captopril and enalapril in patients with severe hypertension

1 reference

12 December 2020

A comparison of enalapril plus hydrochlorothiazide with standard triple therapy in renovascular hypertension

1 reference

12 December 2020

Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.

1 reference

12 December 2020

Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure

1 reference

12 December 2020

Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations

1 reference

12 December 2020

Enalapril treatment in a patient with impaired renal function and intolerance to captopril

1 reference

12 December 2020

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

1 reference

12 December 2020

Selectivity of converting-enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions

1 reference

12 December 2020

Captopril-Induced Functional Renal Insufficiency in Patients with Bilateral Renal-Artery Stenoses or Renal-Artery Stenosis in a Solitary Kidney

1 reference

12 December 2020

Protracted effect of converting-enzyme inhibition on the rat's response to intraarterial bradykinin

1 reference

12 December 2020

Renal Prostaglandin E in the Hypotensive Mechanism of MK-421 in Conscious Rats

1 reference

12 December 2020

Cardiac and haemodynamic effects of enalapril

1 reference

12 December 2020

MK 421 and prevention of genetic hypertension development in young spontaneously hypertensive rats

1 reference

12 December 2020

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"

1 reference

12 December 2020

Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK)

1 reference

12 December 2020

Mechanism for hypotensive action of angiotensin converting enzyme inhibitors

1 reference

12 December 2020

Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency

1 reference

12 December 2020

2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats

1 reference

12 December 2020

Structural changes of large arteries in sustained essential hypertension

1 reference

12 December 2020

Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure

1 reference

12 December 2020

Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor

1 reference

12 December 2020

Total serum angiotensin converting enzyme activity in rats and dogs after enalapril maleate (MK-421)

1 reference

12 December 2020

Pharmacology of Converting Enzyme Inhibitors: New Aspects

1 reference

12 December 2020

Renal glycosuria and azotemia after enalapril maleate (MK-421)

1 reference

12 December 2020

Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension.

1 reference

12 December 2020

Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics

1 reference

12 December 2020

Clinical pharmacology of enalapril

1 reference

12 December 2020

Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure

1 reference

12 December 2020

Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats

1 reference

12 December 2020

Comparative Antihypertensive Effects of Enalapril Maleate and Hydrochlorothiazide, Alone and in Combination

1 reference

12 December 2020

Effect of the angiotensin I converting enzyme inhibitor, MK-421, on experimentally induced drinking

1 reference

12 December 2020

Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor mk 421 (enalapril) in captopril-intolerant patients

1 reference

12 December 2020

Repeated renal failure with captopril

1 reference

12 December 2020

Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor, MK421 (enalapril), independent of blockade of angiotensin II formation

1 reference

12 December 2020

Regression of left ventricular hypertrophy from systemic hypertension by enalapril

1 reference

12 December 2020

Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure

1 reference

12 December 2020

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

1 reference

12 December 2020

Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system

1 reference

12 December 2020

Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension

1 reference

12 December 2020

Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension

1 reference

12 December 2020

Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.

1 reference

12 December 2020

Effects of enalapril, a new converting enzyme inhibitor, in hypertension

1 reference

12 December 2020

Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm

1 reference

12 December 2020

Regulation of angiotensin converting enzyme

1 reference

12 December 2020

Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs

1 reference

12 December 2020

Duration of Action and Short-Term Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1 reference

12 December 2020

An overview of the clinical pharmacology of enalapril

1 reference

12 December 2020

Prolonged hypotension after fever during enalapril treatment

1 reference

12 December 2020

Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521

1 reference

12 December 2020

Pharmacokinetics of repeated single oral doses of enalapril maleate (mk-421) in normal volunteers

1 reference

12 December 2020

Effect of acute oral administration of captopril and MK-421 on vascular angiotensis converting enzyme activity in the spontaneously hypertensive rat

1 reference

12 December 2020

Responses of the kallikrein-kinin system to angiotensin converting enzyme inhibitors in the rat

1 reference

12 December 2020

Effect of enalapril at rest, during tilt, static and dynamic exercise in systemic hypertension

1 reference

12 December 2020

Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo

1 reference

12 December 2020

Enalapril Worldwide Experience

1 reference

12 December 2020

A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension

1 reference

12 December 2020

Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients

1 reference

12 December 2020

The role of angiotensin II in the development of hypertension and in the maintenance of glomerular filtration rate during 48 hours of renal artery stenosis in conscious dogs

1 reference

12 December 2020

Effect of enalapril on ventricular arrhythmias in congestive heart failure

1 reference

12 December 2020

Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects

1 reference

12 December 2020

Leakage of angiotensin converting enzyme inhibitors from the cerebral ventricles into the peripheral circulation in conscious, spontaneously hypertensive rats.

1 reference

12 December 2020

Enalapril in low-renin essential hypertension

1 reference

12 December 2020

Effects of repeated doses of enalapril on renal function in man.

1 reference

12 December 2020

Hemodynamic and humoral responses to enalapril and nifedipine in the rat.

1 reference

12 December 2020

Potentiation of depressor responses to arachidonic acid by angiotensin converting enzyme inhibitors in the rat

1 reference

12 December 2020

Hemodynamic and renal function in essential hypertension during treatment with enalapril

1 reference

12 December 2020

Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension

1 reference

12 December 2020

The clinical pharmacology of enalapril

1 reference

12 December 2020

Influence of captopril and enalapril on regional vascular alpha-adrenergic receptor reactivity in SHR

1 reference

12 December 2020

The clinical pharmacology of antihypertensive drugs

1 reference

12 December 2020

Reproducibility of acute captopril-induced renal insufficiency with enalapril

1 reference

12 December 2020

Chronic effects of enalapril on blood pressure, stroke, plasma renin, urinary electrolytes and PGE2 excretion in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Reversible leucopenia associated with angiotensin-converting-enzyme inhibitor MK 421

1 reference

12 December 2020

Effective dose range of enalapril in mild to moderate essential hypertension

1 reference

12 December 2020

Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung

1 reference

12 December 2020

Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure

1 reference

12 December 2020

A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension

1 reference

12 December 2020

Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients.

1 reference

12 December 2020

Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor

1 reference

12 December 2020

Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.

1 reference

12 December 2020

Antihypertensive activity of SCH 31846, a non-sulfhydryl angiotensin-converting enzyme inhibitor.

1 reference

12 December 2020

Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect

1 reference

12 December 2020

A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension

1 reference

12 December 2020

Effects of a new angiotensin-converting enzyme inhibitor, MK 421, in normal men and patients

1 reference

12 December 2020

New evidence for brain angiotensin and for its role in hypertension

1 reference

12 December 2020

Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I

1 reference

12 December 2020

Tolerance and safety of enalapril

1 reference

12 December 2020

Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study

1 reference

12 December 2020

Enalapril and hypertension

1 reference

12 December 2020

Rash, eosinophilia, and hyperkalaemia associated with enalapril

1 reference

12 December 2020

Enalapril in the treatment of hypertension with renal artery stenosis

1 reference

12 December 2020

Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril

1 reference

12 December 2020

Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man

1 reference

12 December 2020

Long-term clinical experience with enalapril in essential hypertension

1 reference

12 December 2020

Initial dose of enalapril in hypertension

1 reference

12 December 2020

Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.

1 reference

12 December 2020

ACE inhibitors: enalapril and captopril compared

1 reference

12 December 2020

"Scalded mouth" caused by angiotensin-converting-enzyme inhibitors

1 reference

12 December 2020

Angiotensin-Converting Enzyme Inhibitory Activity of SCH 31846, a New Non-Sulfhydryl Inhibitor

1 reference

12 December 2020

Enalapril: a review of human pharmacology.

1 reference

12 December 2020

Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure

1 reference

12 December 2020

Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes

1 reference

12 December 2020

Influence of Food on the Bioavailability of Enalapril

1 reference

12 December 2020

Controlled trial of enalapril in congestive cardiac failure

1 reference

12 December 2020

The brain angiotensin system: subcellular localization and interferences with converting enzyme inhibitors

1 reference

12 December 2020

Enalapril versus triple-drug therapy in the treatment of renovascular hypertension

1 reference

12 December 2020

Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure.

1 reference

12 December 2020

Angiotensin-converting-enzyme inhibitors in treatment of heart failure

1 reference

12 December 2020

Comparative Effects of Enalapril, Enalaprilic Acid and Captopril in Blocking Angiotensin I-Induced Pressor and Dipsogenic Responses in Spontaneously Hypertensive Rats

1 reference

12 December 2020

Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension

1 reference

12 December 2020

The effects of converting enzyme inhibitors on plasma angiotensinogen and plasma aldosterone in sodium-depleted rats

1 reference

12 December 2020

An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension

1 reference

12 December 2020

Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects

1 reference

12 December 2020

Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.

1 reference

12 December 2020

Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives

1 reference

12 December 2020

10.2165/00003495-198631030-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

0 references

1 reference